Search for stocks /

Atul Ltd Q2 FY26 – The ₹17,500-Cr Chemical Monk Who Hates Debt, Drama, and Doing Anything Quickly


1. At a Glance – The Silent Sage of Ankleshwar

At ₹ 5,952 a share, Atul Ltd sits quietly in its 1,200-acre ashram in Valsad, Gujarat, watching small-caps fight for attention while it counts inventory like rosary beads.
Market-cap ₹ 17,524 crore. P/E 32×. Debt ₹ 186 crore (essentially pocket change). ROCE 12.8 %. ROE 9.1 %.

Q2 FY26 was like a well-executed yoga pose — balanced but unexciting: Revenue ₹ 1,552 crore (+11 % YoY), PAT ₹ 182 crore (+31 %). Operating margin 17 %. No drama, no fire — just chemistry and patience.
While rivals were busy raising bonds and blood pressure, Atul quietly expanded plants and added 50,000 TPA of liquid epoxy resin capacity. A boring company? Yes. Profitable? Also yes.


2. Introduction – The Chemical Company That Refuses to Trend

Atul is that uncle who never posts on LinkedIn but owns half the town. Incorporated in 1947 by Kasturbhai Lalbhai (yes, the textile tycoon from the Lalbhai Group), Atul was literally inaugurated by Jawaharlal Nehru. Since then, it has spent 78 years doing what every finance student hates — compound slowly.

It was India’s first producer of vat dyes, 2,4-D acid, carbamite, para-cresol, and even tissue-culture date palms. If you own a pair of jeans, sprayed a crop, painted a wall, or taken a painkiller — chances are, Atul supplied something that made it possible.

And yet, the stock is down 23 % YoY. Because the market has the attention span of a fruit fly. No acquisition news, no debt, no Twitter CEO quotes — so Atul gets ignored. Perfect time for an auditor like us to poke around.


3. Business Model – WTF Do They Even Do?

Atul’s business is split like a balanced chemical reaction:

A. Life Science Chemicals (~30 % of Revenue)

  • Crop Protection: Herbicides, insecticides, fungicides, biostimulants. New launch “Sindica” targets sugarcane weeds with patent backing.
  • Pharma & Aromatics-I: APIs and intermediates for pain management, antibacterials, and aroma chemistry.

B. Performance & Other Chemicals (~70 %)

  • Aromatics-II, Bulk Chemicals, Colors & Polymers.
    From dyes for Levi’s to epoxy resins for wind turbine blades.

Over 900 products, 400 formulations, 50 brands — names like Zura, Salix, Loxo, Rymix, Amsac. If Breaking Bad were shot in Gujarat, this would be the set.

Distribution = 3,800 suppliers, 2,000 distributors, 38,000 retailers, serving ~4,000 customers across 83 countries.
This is not a startup; it’s a supply chain religion.


4. Financials Overview – Numbers Don’t Lie

Source table
MetricLatest Qtr (Q2 FY26)YoY (Q2 FY25)Prev Qtr (Q1 FY26)YoY %QoQ %
Revenue (₹ Cr)1,5521,3931,478+11.4 %+5 %
EBITDA (₹ Cr)267243236+9.9 %+13 %
PAT (₹ Cr)182140132+31 %+37 %
EPS (₹)60.946.543.4+31 %+40 %

Comment: The company prints profits like a government mint — slowly, neatly, without ink smudges. Margins expanded to 17 %, thanks to lower raw-material volatility and better mix in epoxy resins.


5. Valuation Discussion – Fair Value Range Only

Method 1: P/E Approach

EPS TTM ₹ 184
Industry P/E ≈ 33×
Apply 10 % “boring discount.”
→ Fair Range = ₹ 184 × (28 – 33) = ₹ 5,150 – ₹ 6,070

Method 2: EV/EBITDA

EV = ₹ 17,628 Cr; EBITDA ≈ ₹ 1,095 Cr → 16×
Peers trade 14–18× (Deepak Nitrite 16×, Vinati ~40×).
→ Fair Value = ₹ 5,400 – ₹ 6,200**

Method 3: DCF

Assume 7 % CAGR growth, WACC 10.5 %, terminal 4 %.
DCF Equity Value ≈ ₹ 5,200 – ₹ 6,000**

Fair Value Range: ₹ 5,100 – ₹ 6,100 (educational)
CMP ₹ 5,952 — bang in the middle.
Disclaimer: Educational purpose only; not advice.


6. What’s Cooking – News, Triggers & Drama

  • Sindica Launch: Patented sugarcane herbicide — first in India.
  • Liquid Epoxy Expansion: +50,000 TPA commissioned Oct 2024.
  • JV with Buckman: 50:50 partnership for water treatment chemicals (India + Sri Lanka).
  • USFDA EIR Received: Atul Bioscience cleared — opens doors for regulated market APIs.
  • Insurance Payout: Fire loss (2022) fully settled FY25 — ₹ recovery credited.
  • Capex: ₹ 2,000 Cr FY22–FY25 aims +₹ 2,300 Cr sales.
  • Buyback 2023: ₹ 50 Cr — proof of

One Response

  1. The company has seen shrinking margins since 2021 with net profits still lower by 20% of those days. And the same reflects on the stock price also which has corrected almost 50% since its peak. So, calling it a steady solid compounder might not be correct.

    Could you shed some light on this history and how is the company poised for the medium term future.

Leave a Reply

error: Content is protected !!